MEGGLE to launch latest InhaLac® offering at RDD Europe 2023

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Wasserburg GmbH (MEGGLE) will be a prominent presence at May’s Respiratory Drug Delivery (RDD) in the South of France conference, using the event as a launch platform for its latest inhalable lactose grade, InhaLac® 180.

InhaLac® 180 is tailored to dry powder inhalation (DPI) applications with a highly uniform particle size distribution (PSD) of X10=5-15μm, X50=50-100μm, and X90=120-160μm and characterized by the typical flow and surface characteristics of milled lactose.

Expanding developer’s tool box

The launch is designed to bring MEGGLE lactose excipient quality to a particular customer need identified in feedback, also expanding the tool box for developers.

“This is a very popular and frequently used PSD distribution among the DPI community,” commented MEGGLE Project Manager for DPI R&D, Katja Milkreiter, who played a leading role in developing the product.

Advancing DPI development

“This new grade should open the way to further DPI developments and help developers of generic formulations to fulfill requirements,” added Dr. Constanze Müller, MEGGLE Business Development Inhalation, who will also be present at the Antibes conference.

“This is a significant expansion of our portfolio that allows us a broader positioning in the market,” explained Dr. Müller.

About MEGGLE

Bavarian-based MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About RDD Europe 2023

The Respiratory Drug Delivery (RDD) series of conferences impact regulatory and scientific policies worldwide, and are recognized as among the premier international meetings in this therapeutic area.

The success of the Respiratory Drug Delivery (RDD) Conference series is founded on the selection of internationally renowned speakers, lively audience participation, and the financial support of organizations with focus on all aspects of pulmonary and nasal drug delivery.

RDD 2023 will be a four-day event opening May 2, 2023, at the Palais des Congrès Antipolis in Antibes on France’s Côte d’Azur, with an online dimension providing access to content through to end of June.

Apart from an array of expert speakers, the event will include Knowledge Spaces that organize scientific content by theme so that related presentations, posters and company exhibits are together online, table top exhibitions, discussion sessions and workshops, networking events and the RDD VCU Peter R. Byron Graduate Student Award presented to the highest quality research.

The event is organized by RDD Online with further information at: https://www.rddonline.com/rdd

Resources

Click on MEGGLE at RDD Europe 2023 to connect with MEGGLE via the event.
Click on MEGGLE Milled lactose for pulmonary and nasal drug delivery for further information.
Click on MEGGLE DPI technologies to view video.